2m 2m 2m 2m 2m 2m 2m
- N/AMarket Cap
- -91.67%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
Fifty 1 Labs (FITY)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 68
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.
Fifty 1 Labs Inc. has signed a Letter of Intent to acquire BioSpark AI Technologies Inc., a Vancouver-based AI company specializing in clinical data extraction and analysis. The proposed acquisition involves 25 million common shares and aims to strengthen Fifty 1 Labs' position in AI-powered healthcare solutions.
09/30/2025, 9:56 AM • Benzinga
Peers
Statistics
MoreInformation as of 11/12/2026
Company Profile
Fifty 1 Labs, Inc., a biotechnology and life sciences company, which focuses on peptide products, peptide discovery, AI-enabled research, and clinical development in the United States. The company provides sports supplements; peptides; telepath products, as well as health and wellness solutions. It offers supplements such as, pre-workout formulas, BCAAS, ION+ electrolyte formula, turmeric gummies, and ashwagandha gummies. The company was formerly known as Consumer Automotive Finance, Inc. and changed its name to Fifty 1 Labs, Inc. in March 2025. Fifty 1 Labs, Inc. was incorporated in 1998 and is based in Vancouver, Canada.
Key Executives
- Alind Gupta
- Joel Gagnier
- Nima Sakian
- Brandon Spikes
- Martin Mills
Current Ownership Distribution
- Other571.9M (100.00%)
- Insiders9,500 (0.002%)
- Institutions0 (0.00%)
- Mutual Funds0 (0.00%)